HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Kraft vet Loranger joins GSK Consumer

You may also be interested in...

USANA Plans OTC Entry As Nutritional MLM Competition Heats Up

USANA Health Sciences plans to expand beyond nutritionals into nonprescription pharmaceuticals.

People In Brief

Orr moves to Ocean Nutrition board: President, CEO and co-founder Robert Orr leaves Ocean Nutrition Canada's helm to become board chairman, making way for Martin Jamieson to take the top post. Jamieson, a former food technologist, was executive VP of Loblaw Brands, the private label unit of Loblaw Companies, and also spent time as president of Robin Hood Multifoods and Pillsbury Canada. Ocean Nutrition, based in Dartmouth, Nova Scotia, intends to focus on international and food sector growth for its omega-3 ingredients, the firm said July 6

People In Brief

Bellus names Bellini president, Cavell deputy chair: Canadian firm Bellus Health Inc. appoints Roberto Bellini to succeed his father, Francesco Bellini, as president and CEO effective Jan. 1. The parent company of nutraceutical firm Ovos Natural Health said Dec. 15 that Bellini has been with the Montreal-based firm for eight years, most recently as VP of business development. Francesco Bellini announced his resignation in June but will remain chairman. Bellus also named Charles Cavell deputy chairman. He has been a board member since June 2009. Ovos plans a 2010 U.S. launch of its Vivimind cognitive health supplement, contingent upon FDA's go-ahead for what the firm attests would be the first new dietary ingredient to reach U.S. stores after failing as an investigational new drug candidate. Ovos already markets the homotaurine-based product in other countries (1"The Tan Sheet" Dec. 21, 2009)


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts